The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

V.c

Pleural thickening - Fibrothorax

A history of exposure to asbestos may increase both likelihood and speed of progression of ergot-induced pleural pathology (PMID: 9493644). A search for retroperitoneal fibrosis and ureteral compression is indicated (PMID 25455951)

Publications

Tintner R, Manian P, Gauthier P, Jankovic J

Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.

Archives of neurology. 2005;62(8):1290-5

Danoff SK, Grasso ME, Terry PB, Flynn JA

Pleuropulmonary disease due to pergolide use for restless legs syndrome.

Chest. 2001;120(1):313-6

Pfitzenmeyer P, Foucher P, Dennewald G, Chevalon B, Debieuvre D, Bensa P, Piard F, Camus P

Pleuropulmonary changes induced by ergoline drugs.

The European respiratory journal. 1996;9(5):1013-9

Gefter WB, Epstein DM, Bonavita JA, Miller WT

Pleural thickening caused by Sansert and Ergotrate in the treatment of migraine.

AJR. American journal of roentgenology. 1980;135(2):375-7

Malaquin F, Urban T, Ostinelli J, Ghedira H, Lacronique J

Pleural and retroperitoneal fibrosis from dihydroergotamine.

The New England journal of medicine. 1989;321(25):1760